A phase 1/2 study of talazoparib (BMN 673), an oral poly(ADP-ribose) polymerase inhibitor, plus temozolomide in children with refractory or recurrent malignancies: A Children's Oncology Group phase 1 consortium study (ADVL1411). (December 2016) - Schafer, E.S.; Rau, R.E.; Liu, X.; Minard, C.G.; Reid, J.M.; Fox, E.; Weigel, B.J.; Blaney, S.M.